银屑病治疗的演变格局

The Evolving Landscape of Psoriasis Treatment.

作者信息

Armstrong April W, Gordon Kenneth B, Menter M Alan, Wu Jashin J

机构信息

Associate Professor of Clinical Dermatology Associate Dean for Clinical Research Keck School of Medicine of the University of Southern California Los Angeles, California.

Professor and Chair Department of Dermatology Medical College of Wisconsin Milwaukee, Wisconsin.

出版信息

Semin Cutan Med Surg. 2018 Feb;37(2S):S39-S43. doi: 10.12788/j.sder.2018.009.

DOI:10.12788/j.sder.2018.009

PMID:29614136

Abstract

The process of discovering new drugs for plaque psoriasis has revealed much about the multisystemic nature of the disease. Current and emerging biologic agents may reliably achieve a Psoriasis Area and Severity Index (PASI 75) up to 90. Initially, clinicians select therapies based on the severity of the psoriasis. Although mild disease can be treated with topical agents, for patients with moderate to severe disease, concurrent therapy with oral systemic agents, biologics, and/ or phototherapy needs to be considered. In some instances, clinicians may need to combine medications to provide patients with rapid relief of symptoms. Semin Cutan Med Surg 37(supp2):S39-S43.

摘要

寻找斑块状银屑病新药的过程揭示了该疾病多系统性质的诸多方面。目前及新出现的生物制剂可可靠地使银屑病面积和严重程度指数（PASI 75）达到90。最初，临床医生根据银屑病的严重程度选择治疗方法。虽然轻度疾病可用局部用药治疗，但对于中度至重度疾病患者，需要考虑联合口服全身用药、生物制剂和/或光疗。在某些情况下，临床医生可能需要联合用药，以便为患者迅速缓解症状。《皮肤外科医学杂志》37（增刊2）：S39 - S43。